Maxim Group Sticks to Their Buy Rating for PAVmed (PAVM)

In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on PAVmed (PAVMResearch Report), with a price target of $5.00. The company’s shares closed last Friday at $1.99.

According to, Vendetti is a 4-star analyst with an average return of 3.9% and a 47.5% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ra Medical Systems, and Sensus Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PAVmed with a $5.00 average price target.

See today’s analyst top recommended stocks >>

Based on PAVmed’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $6.24 million. In comparison, last year the company had a GAAP net loss of $6.83 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.